Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of Inhaled Nitric Oxide in Cystic Fibrosis
NCT00570349Phase 2Completed
- Sponsor
- Mallinckrodt Pharmaceuticals
- Start
- Jul 2004
- Primary completion
- Dec 2008
- Modality
- Transdermal Patches, Inhalation Devices, Hydrogel Systems
- Countries
- 1
01
Overview
A Phase 2 trial of Nitric oxide-releasing solution in cystic fibrosis (CF), sponsored by Mallinckrodt Pharmaceuticals. Started Jul 2004; status: completed.
02
Drugs
Nitric oxide-releasing solution
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on NCT00570349.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00570349.